The Food and Drug Omnibus Reform Act of 2022 (FDORA) was signed into law, amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. It includes provisions that impact various aspects of the FDA-regulated industry. Some key provisions include reauthorizations of FDA programs, reporting requirements for approved biological products, improvements in… Continue reading Implications of The Food and Drug Omnibus Reform Act of 2022 (FDORA) for the clinical trial industry
Implications of The Food and Drug Omnibus Reform Act of 2022 (FDORA) for the clinical trial industry
